文献速递前列腺癌

阿帕他胺作为起始治疗对真实世界转移性激素敏感性前列腺癌患者生存结局的影响(OASIS)

Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS).
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-12-20

该回顾性观察性队列研究利用美国ConcertAI RWD 360前列腺癌数据集,纳入2018年1月至2023年6月新诊断的4937例转移性激素敏感性前列腺癌患者,评估一线阿帕他胺+雄激素剥夺治疗与其他延长生存方案的真实世界疗效。结果显示阿帕他胺+ADT在24个月OS、TTCR及PSA缓解深度上均优于恩扎卢胺+ADT、阿比特龙+泼尼松+ADT和单用ADT。

要点

  • 阿帕他胺+ADT组3个月PSA50/PSA90/不可测PSA比例分别为70%/49%/44%,高于其他方案组。
  • 阿帕他胺+ADT组24个月OS为66%、TTCR为77%,均优于恩扎卢胺、阿比特龙和单用ADT组。
  • 与恩扎卢胺+ADT相比,阿帕他胺+ADT死亡风险aHR为0.66(95%CI 0.51-0.87)。

核心结论

  • 在美国真实世界临床实践中,mHSPC一线阿帕他胺+ADT与其他延长生存治疗相比,与统计学显著更长的OS、更长的TTCR以及更快更深的PSA缓解相关。
  • 尽管强化治疗有效性增加,仍有大量患者未接受强化治疗。

研究设计与样本

  • 回顾性、观察性队列研究,使用ConcertAI RWD 360前列腺癌数据集的电子医疗记录。
  • 纳入2018年1月至2023年6月新诊断的mHSPC患者,随访至死亡、随访结束或2024年1月(以先发生者为准)。
  • 共纳入4937例患者:阿帕他胺+ADT组315例,恩扎卢胺+ADT组1181例,阿比特龙+泼尼松+ADT组1760例,多西他赛+ADT组432例,单用ADT组1249例。
  • 采用Kaplan-Meier法估计OS、PSA50/PSA90时间、不可测PSA(≤0.2 ng/ml)时间和去势抵抗时间(TTCR)。
  • 采用逆概率治疗加权多变量Cox比例风险模型估计校正风险比(aHR),校正年龄、合并症、BMI和基线PSA。

主要发现

  • 3个月时达到PSA50、PSA90和不可测PSA的患者比例在阿帕他胺+ADT组分别为70%、49%、44%,显著高于恩扎卢胺+ADT组(60%/38%/32%)、阿比特龙+泼尼松+ADT组(59%/37%/33%)和单用ADT组(32%/15%/32%)。
  • 24个月时OS和TTCR在阿帕他胺+ADT组分别为66%和77%,显著长于恩扎卢胺+ADT组(55%/63%)、阿比特龙+泼尼松+ADT组(59%/67%)和单用ADT组(54%/57%)。
  • 与恩扎卢胺+ADT相比,阿帕他胺+ADT起始治疗与显著降低的死亡风险相关(aHR 0.66,95%CI 0.51-0.87)。
  • 与阿比特龙+泼尼松+ADT相比,阿帕他胺+ADT起始治疗与显著降低的死亡风险相关(aHR 0.72,95%CI 0.55-0.94)。
  • 与单用ADT相比,阿帕他胺+ADT起始治疗与显著降低的死亡风险相关(aHR 0.64,95%CI 0.49-0.84)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen receptor pathway inhibitors (apalutamide [APA], enzalutamide [ENZ], abiraterone acetate plus prednisone [AAP]) combined with androgen-deprivation therapy (ADT) are effective life-prolonging treatment options for metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the impact of upfront therapy for mHSPC on outcomes in real-world clinical practice in the United States. METHODS: This retrospective, observational cohort study used electronic healthcare records from the ConcertAI RWD 360 Prostate Cancer Dataset. All patients with newly diagnosed mHSPC from January 2018 to June 2023 were enrolled and followed-up until death, end of follow-up, or January 2024, whichever occurred first. Kaplan-Meier methods were used to estimate overall survival (OS), time to PSA50/PSA90 (50%/90% decline in PSA from baseline, respectively), time to undetectable PSA ( ≤ 0.2 ng/ml), and time to castration resistance (TTCR). Adjusted hazard ratios (aHR) were estimated using inverse probability of treatment weighted multivariate Cox proportional models adjusted for age, comorbidities, BMI, and baseline PSA. RESULTS: 4937 patients with mHSPC were included in the analysis: 315 received upfront APA + ADT, 1181 ENZ + ADT, 1760 AAP + ADT, 432 docetaxel (DTX) + ADT, and 1249 ADT alone. Percentages of patients reaching PSA50, PSA90, and undetectable PSA at 3 months were significantly higher for APA + ADT (70%/49%/44%, respectively) compared to ENZ + ADT (60%/38%/32%), AAP + ADT (59%/37%/33%) and ADT alone (32%/15%/32%). OS and TTCR were also significantly longer for APA + ADT (66%/77% respectively at 24 months) vs ENZ + ADT (55%/63%) AAP + ADT (59%/67%) and ADT alone (54%/57%). Starting treatment with APA + ADT was associated with a significantly reduced risk of death compared with ENZ + ADT (aHR, 95%CI) (0.66, 0.51-0.87), AAP + ADT (0.72, 0.55-0.94), and ADT alone (0.64, 0.49-0.84). CONCLUSIONS: Numerous patients were not treated with intensified therapies despite their increased effectiveness. First-line APA + ADT in mHSPC was associated with statistically significantly longer OS, longer TTCR, and faster and deeper PSA responses than other life-prolonging treatments in real-world clinical practice in the US.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Maughan BL, Liu Y, Mundle S, et al. Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS). Prostate Cancer Prostatic Dis. 2024. PMID: 39702472. doi:10.1038/s41391-024-00929-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。